What Are Exosomes? A Research-Reagent Overview
Exosomes are small extracellular vesicles of endosomal origin that carry proteins, lipids, and nucleic acids between cells. This page summarises their biology and the laboratory and clinical research in which they are us
Exosomes are a subclass of extracellular vesicles, typically 30–150 nm in diameter, that form in the endosomal system and are released from cells on fusion of multivesicular bodies with the plasma membrane. They are distinguished from microvesicles and apoptotic bodies by their endosomal biogenesis and by markers such as tetraspanins (CD9, CD63, CD81), Alix, and TSG101. Because they carry proteins, lipids, and nucleic acids, exosomes are studied both as intercellular signalling vehicles and as a source of disease biomarkers. The evidence block for this page does not supply a sequence, formula, or molecular weight for exosomes as a class; those identifiers are not applicable to a heterogeneous vesicle population.
Research on exosomes centres on their cargo and on the pathways that cargo engages in recipient cells. Across the studies cited here, the recurring mechanistic themes are receptor tyrosine kinase signalling (including EGFR), AMPK/mTOR metabolic signalling, and the TGF-β/SMAD and Hippo/TEAD1 axes.
Research Studies
Urinary exosomes and podocyte injury markers in diabetic kidney disease
A clinical trial is examining podocyte-specific injury markers — nephrin, podocalyxin, and Wilms' tumour (WT-1) protein — in urinary exosomes from African American Veterans with albuminuric stage 2 and 3 chronic diabetic kidney disease [1]. Participants are treated with empagliflozin, finerenone, or combination therapy. Secondary objectives include correlating exosome-based podocyte-specific proteins with standardised kidney injury biomarkers (urine albumin/creatinine ratio and estimated GFR) and with systemic inflammatory markers including IL-1, IL-6, IL-12, hs-CRP, and measures of arterial stiffness [1].
Melanoma exosomal hsa-miR-221-5p and keratinocyte LL-37 suppression
In clinical specimens, cathelicidin LL-37 was spatially suppressed in tumour-adjacent epidermis relative to distal regions [2]. Melanoma-derived exosomes suppressed keratinocyte LL-37 expression, driven in part by exosomal hsa-miR-221-5p through impaired sustained EGFR signalling. Keratinocyte-derived LL-37 curtailed melanoma cell migration, invasion, and epithelial–mesenchymal transition, restrained tumour growth in vivo, and was associated with a tumour immune microenvironment enriched in M1 macrophages [2].
FGF21-modified adipose stem cell exosomes and fibroblast glycolysis
Adipose-derived mesenchymal stem cells overexpressing fibroblast growth factor 21 were used to isolate FGF21-enriched exosomes (Exo@FGF21), characterised by transmission electron microscopy and nanoparticle tracking analysis [3]. The study aimed to elucidate how these engineered exosomes promote wound healing, with activation of fibroblast glycolysis through AMPK/mTOR signalling proposed as the mechanism [3].
Cerebrolysin-treated endothelial cell exosomes and permeability
In an in vitro endothelial permeability assay, exosomes released by Cerebrolysin-treated cerebral endothelial cells (Cerebro-Exos) were compared with exosomes from untreated cells (Naïve-Exos) [4]. Stoichiometric analysis showed marked differences in cargo profiles, with Cerebro-Exos highly enriched in metabolic and tight junction-related proteins. Cerebro-Exos had a superior effect to Naïve-Exos on restoring endothelial integrity impaired by fibrin and tissue plasminogen activator [4].
Umbilical cord blood-derived stem cells and exosomes in autism spectrum disorder
A 12-month clinical study is testing whether AdiaVita (umbilical cord blood-derived stem cells and exosomes) plus glutathione improves autism symptoms more than glutathione alone in children ages 3–12 [5]. Approximately 100 children with confirmed autism are randomly assigned to receive either monthly intravenous AdiaVita plus intravenous glutathione for 3 months, or intravenous glutathione plus a saline placebo infusion for 2 months; both groups also use a topical glutathione spray twice daily at home. Symptoms are tracked with the Autism Treatment Evaluation Checklist (ATEC) completed by a parent and by a therapist or teacher, with safety monitored through Month 12 [5].
Exosomes in craniofacial and corneal neuropathic pain
A review of regenerative medicine approaches to craniofacial and corneal neuropathic pain describes these conditions as arising from peripheral nerve injury, neuroinflammation, and maladaptive central sensitisation within trigeminal pathways [6]. The review frames regenerative strategies as a shift from symptom suppression toward structural nerve repair and functional restoration, and discusses exosomes among the approaches considered [6].
Neuronal exosomes as biomarkers for exercise effects
A clinical study is examining the brain-based biological pathway by which exercise exerts anxiolytic effects [7]. Investigators will measure brain-derived markers of mitochondrial metabolism (acetyl-L-carnitine) and inflammation (interleukin-6) using technology to isolate neuronal exosomes [7].
Wharton's jelly exosomes with autologous bone marrow cells in liver cirrhosis
A clinical study in patients with liver cirrhosis, irrespective of stage and excluding those with active tumour or other major life-endangering health issues, combines autologous bone marrow-derived mononuclear cells with Wharton's jelly exosomes [8]. The protocol involves harvesting bone marrow mononuclear cells under local anaesthesia, concentrating and viability-testing them, then combining the final product with 2 cc of Wharton's jelly exosomes at 20 billion per dose for intravenous administration [8].
Comparison of exosome sources and models
| Study | Exosome source | Model or population | Key finding |
|---|---|---|---|
| [1] | Urinary exosomes | African American Veterans with albuminuric stage 2–3 diabetic kidney disease | Podocyte-specific proteins (nephrin, podocalyxin, WT-1) measured as injury markers |
| [2] | Melanoma-derived exosomes | Clinical specimens and in vivo models | hsa-miR-221-5p suppresses keratinocyte LL-37 via impaired EGFR signalling |
| [3] | FGF21-modified ADSC exosomes | Wound healing model | Activation of fibroblast glycolysis through AMPK/mTOR signalling |
| [4] | Cerebrolysin-treated CEC exosomes | In vitro endothelial permeability assay | Superior restoration of endothelial integrity vs Naïve-Exos |
| [5] | Umbilical cord blood-derived stem cells and exosomes | Children ages 3–12 with autism spectrum disorder | ATEC symptom tracking over 12 months |
| [7] | Neuronal exosomes | Exercise study | Measurement of acetyl-L-carnitine and IL-6 |
| [8] | Wharton's jelly exosomes | Patients with liver cirrhosis | Combined with autologous bone marrow mononuclear cells |
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Role of Finerenone in African American Veterans With Diabetic Kidney Disease
- [2] Melanoma exosomal hsa-miR-221-5p suppresses keratinocyte LL-37 to promote tumor progression
- [3] FGF21-modified adipose stem cell-derived exosomes promote wound healing by activating fibroblast glycolysis through AMPK/mTOR signaling
- [4] Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability
- [5] Adia Med of Winter Park LLC Autism Spectrum Disorder Research Study
- [6] Regenerative Medicine Approaches to Craniofacial and Corneal Neuropathic Pain
- [7] Biomarkers for Exercise
- [8] Using Autologous Bone Marrow Cells With Wharton Gel Exosomes to Stimulate Hepatic Cell Repair in Liver Cirrhosis